Epigenomics, a molecular diagnostics company developing tests based on DNA
methylation, is developing a test for the methylation of a single gene, PITX2, that can predict recurrence of prostate cancer after radical surgery. This new test is not yet available but it looks worth watching out for. The same company is developing a blood test for early detection of colon cancer. The company presented study results this week at 97th AACR Annual Meeting in Washington D.C., USA. Full stories:

Clinical Study Proves Prognostic Power of Epigenomics’ Biomarker in Prostate Cancer

Epigenomics Presents Data Confirming Screening for Methylated DNA in Blood as Key to Early Colorectal Cancer Detection